RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor abbvie.com ↗
2025-05-27
Organon and Co
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection organon.com ↗
2024-05-20
Teva Branded Pharmaceutical Products R&D, Inc.
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. tevapharm.com ↗
2024-04-30
Teva Branded Pharmaceutical Products R&D, Inc.
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) tevapharm.com ↗
2024-04-15
Organon and Co
Organon’s HADLIMA™ (adalimumab-bwwd) and NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) Added to Mark Cuban’s Cost Plus Drugs organon.com ↗
2024-02-23
Teva Branded Pharmaceutical Products R&D, Inc.
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® tevapharm.com ↗
2024-02-20
Organon and Co
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary organon.com ↗
2023-11-07
Organon and Co
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira® organon.com ↗
2023-08-01
Organon and Co
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar organon.com ↗
2023-07-01
Organon and Co
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator organon.com ↗
2023-07-01
Novartis Pharmaceuticals
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space novartis.com ↗
2023-04-03
Novartis Pharmaceuticals
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation novartis.com ↗
2023-03-21
Novartis Pharmaceuticals
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation novartis.com ↗
2023-01-31
Amgen
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES amgen.com ↗
2023-01-30
Novartis Pharmaceuticals
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar novartis.com ↗
2022-08-17
Organon and Co
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd) organon.com ↗
2022-07-21
Novartis Pharmaceuticals
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) novartis.com ↗
2022-06-17
Novartis Pharmaceuticals
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA novartis.com ↗
2022-03-08
AbbVie
AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech abbvie.com ↗
2022-01-05
Organon and Co
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate organon.com ↗
2021-02-24
AbbVie
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis abbvie.com ↗
2019-11-18
Pfizer
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions pfizer.com ↗
2019-11-01
Novartis Pharmaceuticals
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis novartis.com ↗
2019-09-25
Takeda
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab takeda.com ↗
2019-06-14
Novartis Pharmaceuticals
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy novartis.com ↗
2019-05-19
Takeda
New Exploratory Data from VARSITY, the First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week ® takeda.com ↗
2019-05-14
AbbVie
AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim abbvie.com ↗
2019-03-09
Takeda
Vedolizumab (Entyvio ® ) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira ® ) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis takeda.com ↗
2018-11-30
AbbVie
AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer abbvie.com ↗
2018-11-06
AbbVie
AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta abbvie.com ↗
2018-10-31
Novartis Pharmaceuticals
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) novartis.com ↗
2018-10-18
AbbVie
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi abbvie.com ↗
2018-10-11
Novartis Pharmaceuticals
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access novartis.com ↗
2018-10-11
AbbVie
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz abbvie.com ↗
2018-10-08
AbbVie
AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting abbvie.com ↗
2018-07-27
Novartis Pharmaceuticals
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) novartis.com ↗
2018-07-17
AbbVie
AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan abbvie.com ↗
Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis abbvie.com ↗
2018-04-05
AbbVie
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis abbvie.com ↗
2018-01-16
Novartis Pharmaceuticals
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA novartis.com ↗
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** novartis.com ↗
2017-11-05
Incyte Corporation
ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo incyte.com ↗
2017-09-28
AbbVie
AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen abbvie.com ↗
2017-09-14
Novartis Pharmaceuticals
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study novartis.com ↗
2017-07-21
AbbVie
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis abbvie.com ↗
2017-05-31
Novartis Pharmaceuticals
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency novartis.com ↗
2017-03-30
AbbVie
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information abbvie.com ↗
2017-03-06
Novartis Pharmaceuticals
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine novartis.com ↗
2017-02-16
Pfizer
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) pfizer.com ↗
2017-02-15
Incyte Corporation
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo incyte.com ↗
2017-01-05
Pfizer
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) pfizer.com ↗
2016-11-14
AbbVie
AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease abbvie.com ↗
2016-11-14
Incyte Corporation
Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes incyte.com ↗
2016-09-23
Amgen
FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases amgen.com ↗
2016-07-12
Amgen
Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab amgen.com ↗
2016-07-07
AbbVie
AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress abbvie.com ↗
2016-06-30
AbbVie
AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis abbvie.com ↗
2016-06-13
Amgen
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab amgen.com ↗
2016-05-27
AbbVie
AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1] abbvie.com ↗
2016-05-19
AbbVie
AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data abbvie.com ↗
2016-04-04
AbbVie
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease abbvie.com ↗
2016-03-02
AbbVie
AbbVie Announces New Dermatology Research from More Than 35 Presentations on HUMIRA® (Adalimumab), Long-Term and Real-World Data at the American Academy of Dermatology 2016 Annual Meeting abbvie.com ↗
2015-11-07
Incyte Corporation
Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis incyte.com ↗
2015-11-03
AbbVie
AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases abbvie.com ↗
2015-10-14
Incyte Corporation
Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study incyte.com ↗
2015-09-10
AbbVie
AbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa abbvie.com ↗
2015-07-30
AbbVie
HUMIRA® (Adalimumab) Approved by European Commission for Moderate to Severe Hidradenitis Suppurativa (HS) abbvie.com ↗
2015-06-26
AbbVie
AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Adult Patients with Active Moderate to Severe Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease abbvie.com ↗
2015-06-09
AbbVie
AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with Severe Chronic Plaque Psoriasis at the 23rd World Congress of Dermatology abbvie.com ↗
2015-05-15
AbbVie
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS) abbvie.com ↗
2015-05-05
AbbVie
AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis abbvie.com ↗
2015-04-01
AbbVie
AbbVie's HUMIRA® (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic Plaque Psoriasis abbvie.com ↗
2015-03-17
AbbVie
AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual Meeting abbvie.com ↗
2015-02-27
AbbVie
AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaque Psoriasis abbvie.com ↗
2015-02-03
Amgen
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis amgen.com ↗
2014-11-13
AbbVie
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) abbvie.com ↗
2014-10-13
AbbVie
AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress abbvie.com ↗
2014-10-06
AbbVie
AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and Older abbvie.com ↗
2014-09-25
AbbVie
AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease abbvie.com ↗
2014-09-11
AbbVie
AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease abbvie.com ↗
2014-05-20
AbbVie
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis abbvie.com ↗
2014-03-20
AbbVie
AbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis abbvie.com ↗
2013-10-03
AbbVie
AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease abbvie.com ↗
2013-06-13
AbbVie
AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis abbvie.com ↗
2013-02-15
AbbVie
AbbVie Announces First Long-term, Patient-Reported Health Outcomes Data for Use of HUMIRA® (Adalimumab) in Patients with Pediatric Crohn's Disease abbvie.com ↗
2012-06-06
Bristol-Myers Squibb
ORENCIA® (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents bms.com ↗
Evidence & citations 4 cited values
Every value below carries the sentence it was read from.
1 source stands behind the page.
Field
Value
Cited text
Known as
Adalimumab-US
ClinicalTrials.gov intervention name — accepted as the source's own labelNCT02237729 ↗
Known as
Adalimumab
“PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗
Known as
Humira
“PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗